ZBIO · Zenas BioPharma, Inc. · Metrics
$28.18
+1.47 (+5.50%)
At close · Oct 20
Return incl. dividend (before tax)
Market Cap
$1.87B
Shares
65.18M
Volume · Oct 20
544.53K
Avg daily vol (3M)
707.21K
ZBIO metrics
66 of 122 screener metrics currently available.
Market overview
2 metricsShare price
$26.71
Market cap
$1.87B
Price action
20 metricsPrice change (1W)
+1.2%
Price change (30D)
-17.9%
Price change (3M)
-13.0%
Price change (6M)
+27.8%
Price change (YTD)
-26.4%
Price change (1Y)
+11.5%
Trailing year
Price change (5Y)
—
52-week high
$43.17
52-week low
$15.20
Change from 52-week high
-38.1%
Change from 52-week low
+75.7%
Annualized volatility
101.6%
Annualized volatility (3M)
55.9%
Beta
0.8
RSI (14D)
45.1
Price vs SMA 50
-11.1%
Price vs SMA 200
+8.6%
Avg volume (3M)
707,207
Relative volume
1.0
Average dollar volume
$21.58M
Company
3 metricsSector
Healthcare
Industry
Biotechnology
Shares outstanding
65.18M
Valuation
12 metricsP / E (TTM)
—
Trailing earnings
PEG ratio
—
EV / revenue
1,496.5×
reciprocal yield 0.1%
EV / EBITDA
—
EV / EBIT
—
P / sales
1,761.1×
reciprocal yield 0.1%
P / book
7.1
reciprocal yield 14.0%
FCF yield
-12.8%
TTM · current market cap
Buyback yield
—
P / FCF
—
P / operating cash flow
—
Earnings yield
-27.5%
Historical valuation
8 metricsP / E historical average (3Y)
—
P / E historical average (5Y)
—
EV / revenue historical average (3Y)
—
EV / revenue historical average (5Y)
—
EV / EBIT historical average (3Y)
—
EV / EBIT historical average (5Y)
—
EV / EBITDA historical average (3Y)
—
EV / EBITDA historical average (5Y)
—
Dividends & buybacks
7 metricsDividend yield
—
Trailing 12 months
Payout ratio
—
Shareholder yield
—
Dividend / share (TTM)
—
Dividend growth YoY
—
Dividend growth streak
—
Last ex-dividend
—
Earnings calendar
2 metricsNext earnings
—
Last earnings
2026-01-05
Profitability
9 metricsGross margin
—
Operating margin
-3,830.6%
Trailing 12 months
Net margin
-3,777.4%
Gross profit (TTM)
—
Operating profit (TTM)
−$475.57M
Net income (TTM)
−$484.38M
Trailing 12 months
Diluted EPS (TTM)
$-9.62
FCF margin
—
Effective tax rate
—
Growth
11 metricsRevenue growth YoY
+100.0%
Year over year
Net income growth YoY
—
Revenue (TTM)
$1.00M
Trailing 12 months
EPS growth YoY
—
Shares change YoY
+50.8%
Year over year · more shares
Revenue CAGR (3Y)
—
Revenue CAGR (5Y)
—
EPS CAGR (3Y)
—
EPS CAGR (5Y)
—
FCF CAGR (3Y)
—
FCF CAGR (5Y)
—
Quality
14 metricsReturn on equity
-196.0%
Return on assets
-69.0%
Debt / equity
0.3
Current ratio
9.9
EBITDA (TTM)
—
Free cash flow (TTM)
−$225.97M
Quick ratio
9.9
Interest coverage
—
Net debt / EBITDA
—
Return on invested capital
—
Trailing 12 months
Net cash
$264.56M
Latest balance sheet
Cash & equivalents
$196.58M
Total assets
$701.69M
Total debt
$78.64M
Cash flow & spend
7 metricsOperating cash flow (TTM)
−$225.97M
Capital expenditures (TTM)
$2,000
R&D (TTM)
$213.47M
SG&A (TTM)
—
Stock compensation (TTM)
$32.73M
R&D / revenue
—
Stock compensation / revenue
—
Ownership (13F)
9 metrics13F filers
146
13F filer change QoQ
+5
Institutional ownership
94.5%
Conviction holders (share of 13F filers)
5.6%
Crowding (high-turnover and private-fund holders)
39.0%
Private-fund adviser ownership
38.4%
Active holders' share change QoQ
+3.5%
Holder tenure
6.2
Price vs estimated holder cost
+12.4%
Ownership (registered funds)
1 metricsIndex-fund ownership
8.7%
Short interest
3 metricsShort interest
18.3%
Latest settlement · 15.5 days to cover
Days to cover
15.5d
Short-squeeze score
67 / 100
Insider activity
2 metricsNet insider buying (90D)
—
Insider-sentiment score
—
Risk flags
1 metricsGoing concern
—